PA (July 27, 2005) – Neuro Kinetics, Inc. (NKI),
manufacturers of medical diagnostic equipment used
worldwide, said today that it has closed the first
phase of its Series B equity raise.
company said it has secured $400,000 of its planned
$1 million in new financing.
are gratified that our new investors share our vision
for our company," said Howison Schroeder, NKI
CEO. "Our company has tremendous opportunity
in the near future as we enhance our existing product
line, introduce new products and strengthen our sales
and marketing initiatives around the world."
manufactures neuro-otologic diagnostic devices used
clinically for balance and dizziness testing in hospitals
and other healthcare facilities, and for advanced research
by universities, government agencies and others. The
company's products currently are in use by neurologists,
otolaryngologists, audiologists, ophthalmologists,
vestibular researchers and others across North
America, and in Australia, Asia and Europe.
soon will introduce its next generation I-Portal® eye-tracking
device designed for widespread use by doctors in their
offices, as well as in hospitals and clinics.
company pioneered the development of the motorized,
modern Barany (rotating) Chair Systems.
and dynamically measuring eye movements related to
neuro-otology and neuro-ophthalmology as a cause of
dizziness is key to finding new, cost-effective preventive
solutions to a wide array of diseases and medical disorders," said
Schroeder. "As societies around the world grapple
with the needs of aging populations while also more
efficiently managing healthcare costs, we believe we
are well positioned for continued success."
more information, please visit http://www.neuro-kinetics.com/.
Buckman Communications, for Neuro Kinetics, Inc.